Strs Ohio Purchases Shares of 26,800 Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• Strs Ohio purchased 26,800 shares of Kiniksa Pharmaceuticals valued at approximately $595,000 during the first quarter, reflecting significant institutional interest in the company.
• Insider trading activity included sales by COO Eben Tessari and CAO Michael R. Megna, with declines of 32.19% and 22.44% in their respective positions.
• Analysts are optimistic about Kiniksa Pharmaceuticals, with several price target increases, and an average rating of "Buy" with a price target of around $41.17.

Strs Ohio purchased a new stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 26,800 shares of the company's stock, valued at approximately $595,000.

Several other institutional investors have also added to or reduced their stakes in the business. Bank of America Corp DE raised its stake in shares of Kiniksa Pharmaceuticals International by 2.2% during the fourth quarter. Bank of America Corp DE now owns 215,772 shares of the company's stock valued at $4,268,000 after acquiring an additional 4,654 shares during the last quarter. Lazard Asset Management LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the fourth quarter valued at about $61,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Kiniksa Pharmaceuticals International by 6.7% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,841 shares of the company's stock valued at $432,000 after acquiring an additional 1,380 shares during the last quarter. Nuveen Asset Management LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 7.3% during the fourth quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock valued at $15,737,000 after acquiring an additional 54,361 shares during the last quarter. Finally, ProShare Advisors LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 35.5% during the fourth quarter. ProShare Advisors LLC now owns 12,807 shares of the company's stock valued at $253,000 after acquiring an additional 3,357 shares during the last quarter. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

KNSA has been the subject of several recent analyst reports. Wedbush reaffirmed an "outperform" rating and set a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research note on Sunday, September 7th. Jefferies Financial Group increased their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday, July 29th. Finally, Wells Fargo & Company increased their price target on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 9th. Six analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $41.17.

Insider Activity at Kiniksa Pharmaceuticals International

In related news, insider Ross Moat sold 3,523 shares of the firm's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $35.31, for a total value of $124,397.13. Following the sale, the insider owned 9,415 shares in the company, valued at approximately $332,443.65. This trade represents a 27.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Eben Tessari sold 16,400 shares of Kiniksa Pharmaceuticals International stock in a transaction on Monday, September 15th. The stock was sold at an average price of $36.46, for a total transaction of $597,944.00. Following the transaction, the chief operating officer owned 34,552 shares in the company, valued at $1,259,765.92. This represents a 32.19% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 561,371 shares of company stock worth $18,825,009. Company insiders own 53.48% of the company's stock.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ:KNSA traded down $0.50 during trading on Friday, reaching $35.42. 489,203 shares of the stock traded hands, compared to its average volume of 393,581. The stock has a 50-day moving average of $32.62 and a two-hundred day moving average of $27.69. Kiniksa Pharmaceuticals International, plc has a 52-week low of $17.82 and a 52-week high of $37.34. The stock has a market cap of $2.62 billion, a P/E ratio of 885.72 and a beta of 0.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The firm had revenue of $156.80 million for the quarter, compared to analysts' expectations of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Sell-side analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.